Competition Bureau resolves concerns related to Elanco’s acquisition of Bayer Animal Health
“Animal health products play a critical role in pet care and in the agri-food sector across the country. The agreement concluded today supports our commitment to take action on matters that are important to Canadians, as it will safeguard competitive prices and product choice for consumers and business owners.”
Commissioner of Competition
Elanco and Bayer notified the Bureau of the agreement regarding BAH on November 22, 2019. The proposed transaction is valued at approximately CAD$10.3 billion.
Under the agreement, the Bureau has approved Dechra Limited and Dechra Veterinary Products LLC as acceptable buyers of Osurnia.
The Bureau worked closely with the U.S. Federal Trade Commission, the European Commission and the Australian Competition and Consumer Commission throughout its review of the transaction.
Bayer Animal Health is a business unit of Bayer AG.
For media enquiries, please contact:
The Competition Bureau, as an independent law enforcement agency, ensures that Canadian businesses and consumers prosper in a competitive and innovative marketplace.
Report a problem or mistake on this page
- Date modified: